The net profit of Sanofi, the pharmaceutical concern from France, grew in the third quarter by 10.3% and amounted to 2 billion 300 million euros. The indicator exceeded the experts' forecasts of 2 billion 140 million euros. Revenues for the quarter of 9 billion 400 million euros were also higher than market estimates of 9 billion 300 million euros. Its growth was 6.3%. Sales of the Genzyme division, which produces vaccines and drugs for the treatment of rare diseases, increased by 36.1%. Growth in revenue from the sale of vaccines was 8.2%. Good quarterly results allowed the company to raise the forecast for the current year for the second time in a year. Now, it expects earnings per share for the year to grow by 4-5%.
Samsung Electronics Co Ltd looks forward to the second half of the year as it expects a larger increase in chip demand brought by new smartphone launches. However, the company warned that the coronavirus crisis and trade disputes carry risks. Samsung, ...
Britain on Wednesday signed a supply deal for up to 60 million doses of a possible COVID-19 vaccine that is being developed by pharmaceutical companies GlaxoSmithKline (GSK) and Sanofi. The financial details of the agreement were not disclosed. However, ...
China’s industrial firms had seen an increase in profits for two consecutive months. This came as the most rapid pace ever recorded in over a year, suggesting that the country’s recuperation from the novel coronavirus pandemic ...
American multinational automaker Ford Motor Co. (F.N) announced on Thursday that its vehicle sales increased by 3% from April to June in mainland China. It would be the first time that the company's first quarterly sales rose in the world's ...
The economy in the European Union will plunge deeper into recession for 2020 and may recover only slightly in 2021 than previously thought, the European Commission predicted on Tuesday. The downbeat assessment of Europe's economy comes as ...